Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity
Crossref DOI link: https://doi.org/10.1007/s00277-017-2931-z
Published Online: 2017-01-31
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chan, Thomas S. Y.
Luk, Tsan-Hei
Lau, June S. M.
Khong, Pek-Lan
Kwong, Yok-Lam
License valid from 2017-01-31